Silence Therapeutics (SLNCF) Asset Utilization Ratio (2021 - 2025)
Historic Asset Utilization Ratio for Silence Therapeutics (SLNCF) over the last 5 years, with Q3 2025 value amounting to 0.17.
- Silence Therapeutics' Asset Utilization Ratio rose 52135.77% to 0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17, marking a year-over-year increase of 52135.77%. This contributed to the annual value of 0.27 for FY2024, which is 716.84% up from last year.
- Per Silence Therapeutics' latest filing, its Asset Utilization Ratio stood at 0.17 for Q3 2025, which was up 52135.77% from 0.16 recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Asset Utilization Ratio ranged from a high of 17108.56 in Q3 2021 and a low of 0.03 during Q3 2024
- Moreover, its 5-year median value for Asset Utilization Ratio was 0.07 (2023), whereas its average is 3454.04.
- In the last 5 years, Silence Therapeutics' Asset Utilization Ratio plummeted by 9999.97% in 2022 and then skyrocketed by 52135.77% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' Asset Utilization Ratio stood at 16582.02 in 2021, then plummeted by 100.0% to 0.04 in 2022, then soared by 49.6% to 0.07 in 2023, then grew by 28.37% to 0.08 in 2024, then soared by 95.73% to 0.17 in 2025.
- Its Asset Utilization Ratio was 0.17 in Q3 2025, compared to 0.16 in Q2 2025 and 0.14 in Q1 2025.